We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

DIASORIN MOLECULAR

DiaSorin Molecular LLC manufactures and distributes innovative molecular diagnostic products on the versatile LIAISON... read more Featured Products: More products

Download Mobile App





Diasorin Molecular’s New Multiplex COVID-19/Influenza Test Receives CE Mark

By LabMedica International staff writers
Posted on 22 Sep 2021
Print article
Image
Image
DiaSorin Molecular (Cypress, CA, USA) has CE marked its Simplexa COVID-19 & Flu A/B Direct kit.

The multiplex test allows for the in vitro qualitative detection and differentiation of nucleic acid from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A virus and influenza B virus from the same patient sample in one reaction well. The assay is designed for use on the LIAISON MDX and is run directly from nasopharyngeal swabs (NPS) without the need for off board extraction.

The assay provides confidence in results through broad strain coverage. Over 80 influenza strains were validated including all of the strains in the CDC panels of the last three years. Emerging SARS-CoV-2 variants including the Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), Epsilon (B.1.427/B.1.429), Zeta (P.2), Eta (B.1.525), Iota (B.1.526), Kappa (B.1.617.1), Lambda (C.37), and Mu (B.1.621) variants were also evaluated to ensure diagnostic coverage.

Flu was nearly nonexistent during the 2020/2021 season, which means that the normally high levels of immunity are much lower in the community, leading to the risk for a potentially high spread next season. The upcoming respiratory illness season will be complicated by the presence of SARS-CoV-2 also circulating in the community. The Simplexa COVID-19 & Flu A/B Direct kit provides the ability for laboratories to efficiently run a single, accurate test to detect the most likely causes of respiratory illness during this flu season. This is especially critical given the difficulty to identify the etiology of the infection based solely on a patient’s clinical presentation. Accurate diagnosis of the virus causing infection is critical for the management of therapeutic regimens along with infection control efforts.

"We are excited to expand our product offering with the launch of this combination kit for detection of SARS-CoV-2 and influenza that can help address concerns in anticipation of this upcoming flu season" said Michelle Tabb, chief scientific officer of DiaSorin Molecular. “We are committed to providing flexible testing options with the new combo kit in addition to our stand-alone COVID-19 assay as well as the triplex for Flu A, Flu B and RSV in order to meet laboratory's evolving needs as the world comes back to a new normal.”
New
Gold Supplier
SARS-CoV-2 Rapid Antigen Test
GLINE-2019-nCoV Rapid Antigen Test
New
Gold Supplier
Fully Automated Batch Immunoanalyzer
Evidence+
New
Gold Supplier
BMP Whole Blood Analyzer
GEM Premier ChemSTAT
New
6-Channel Viscoelastometry Analyzer
ClotPro

Print article

Channels

Molecular Diagnostics

view channel
Image: A cancer cell during cell division (Photo courtesy of [U.S.] National Institutes of Health)

New Method Promises Rapid Isolation of Biomarker-Rich Extracellular Vesicles

A new method for isolating and analyzing cancer biomarkers from extracellular vesicles present in biological fluids is based on a novel magnetic particle based liquid biopsy chip. Extracellular vesicles... Read more

Microbiology

view channel
Image: Colored Transmission electron micrograph of Clostridium difficile bacterium forming an endospore (lower right, red oval). Clostridium difficile produce a toxin that irritates the colon and causes diarrhea (Photo courtesy of Kari Lounatmaa, PhD)

Quantity of Toxin in Stool Correlates with C. difficile Severity

Clostridioides difficile (syn. Clostridium difficile), also known as C. difficile, or C. diff are Gram-positive species of spore-forming bacteria. Clostridioides spp. are anaerobic, motile bacteria, ubiquitous... Read more

Technology

view channel
Image: Non-Invasive Nasal Swab Test Leverages Advanced Genomic Technology to Detect Lung Cancer Risk (Photo courtesy of Veracyte, Inc.)

Non-Invasive Nasal Swab Test Leverages Advanced Genomic Technology to Detect Lung Cancer Risk

A novel, non-invasive nasal swab test could support more timely and accurate lung nodule diagnosis. Veracyte, Inc. (South San Francisco, CA, USA) has announced that new expanded clinical validation data... Read more

Industry

view channel
Image: VSE Cat. No. 84800 with optional mobile table and phenolic work surface (Photo courtesy of HEMCO Corporation)

Hemco Offers VSE Balance Enclosure for Critical Procedures Involving Powders and Liquids

HEMCO Corporation (Independence, MO, USA) is offering its Vented Safety Enclosure (VSE) in 24-, 36- and 48-inch widths to accommodate an analytical balance and other small-scale lab processes.... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.